Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026)

Lantheus Holdings' (LNTH) quarterly Cash from Financing Activities came in at -$11.6 million in Q1 2026, up 36.2% year-on-year from -$8.5 million in Q1 2025, and up 88.47% on a QoQ basis from -$100.8 million in Q4 2025.

Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has 13 years of Cash from Financing Activities data on file, last reported at -$11.6 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 36.2% year-over-year to -$11.6 million in Q1 2026; TTM through Mar 2026 was -$310.0 million, a 158.52% decrease from a year earlier, with the FY2025 full-year figure at -$316.6 million, down 167.08% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$11.6 million, up from -$100.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for LNTH reached as high as $317.8 million in Q4 2022 and fell as low as -$103.7 million in Q4 2024.
  • Historically, Cash from Financing Activities has averaged -$8.7 million across 5 years, with a median of -$4.1 million in 2023.
  • Across the five-year window, Cash from Financing Activities jumped 15235.24% in 2022 and tumbled 99507.07% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $317.8 million in 2022, then sank by 100.14% to -$450000.0 in 2023, then plunged by 22935.33% to -$103.7 million in 2024, then climbed by 2.77% to -$100.8 million in 2025, then soared by 88.47% to -$11.6 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were -$11.6 million in Q1 2026, -$100.8 million in Q4 2025, and -$99.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Lantheus Holdings 6.72 Bn 6.22 Bn 230.92 Mn -11.62 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -11.62 Mn
Mar 31, 2026 -11.62 Mn
Dec 31, 2025 -100.79 Mn
Dec 31, 2025 -100.79 Mn
Sep 30, 2025 -99.17 Mn
Sep 30, 2025 -99.17 Mn
Jun 30, 2025 -98.41 Mn
Jun 30, 2025 -98.41 Mn
Mar 31, 2025 -18.22 Mn
Mar 31, 2025 -18.22 Mn
Dec 31, 2024 -103.66 Mn
Dec 31, 2024 -103.66 Mn
Sep 30, 2024 1.87 Mn
Sep 30, 2024 1.87 Mn
Jun 30, 2024 99,000.00
Jun 30, 2024 99,000.00
Mar 31, 2024 -16.85 Mn
Mar 31, 2024 -16.85 Mn
Dec 31, 2023 -450,000.00
Dec 31, 2023 -450,000.00